The Singaporean IVF treatment market is set to reach USD 0.26 billion in 2030, growing at a CAGR of 9.71% from a valuation of USD 0.10 billion in 2020.
The Singaporean IVF treatment market is expected to experience positive growth owing to the favorable initiatives taken by the government to improve the birth rate in the country. For instance, in June 2022, Singapore’s Ministry of Health announced the launch of a scheme that would provide funding to couples for their pre-implantation genetic testing (PGT) during IVF treatment.
In addition, the government has subsidized the IVF costs that patients would have to pay by gradually rolling out the legislation, which is projected to primarily increase demand for IVF treatment. To illustrate, the Singapore Ministry of Health’s Marriage and Parenthood Schemes allows Singaporean citizens to financially cover the costs of maternity, newborn care, and even conception support through government co-funding, MediSave withdrawals, and other subsidies. The main takeaways of the scheme includes couples applying publicly for Assisted Reproduction (AR) services can get a co-funding of 75% for Assisted Reproduction Technology (ART), including in-vitro fertilisation (IVF) and its variations (with/without ICSI, in-vitro maturation, donor cycles, double stimulation, among others.) for a maximum of 3 fresh and 3 frozen ART cycles (with co-funding caps that vary by citizenship).
Moreover, the high cost of living, coupled with low-income appraisal, has led to less child planning among the residential population in Singapore, owing to which the government has undertaken necessary steps to boost the childbirth rate in this segment.
Singapore's total fertility rate has been steadily decreasing, and it is reported to fall to 0.97 live births per female in 2024 from 1.1 in 2020. The main factors contributing to this decline are high living costs and deferred childbearing, where couples prioritize their careers and changing lifestyles. Apart from delaying, the trend is also seen in more cases of infertility, especially among women aged 30-34. The Department of Statistics Singapore reports that the resident total fertility rate for 2024 stands at 79.4 live births per 1,000 females.
Furthermore, urban couples in the Asia-Pacific region are prone to infertility, and the trend of the average age at first birth pushes the demand for IVF. Moreover, non-biological factors such as pollution and stress have been cited as environmental reasons that further compound the situation, making it a significant opportunity for IVF adoption.
Moreover, the educational development and improvement in employment, societal attitudes, and values have further increased the market scope of IVF treatment as improvements in such demographic trends lead to decisions related to marriage and child planning among couples.
| Report Metric | Details |
|---|---|
| Total Market Size in 2020 | USD 0.10 billion |
| Total Market Size in 2030 | USD 0.26 billion |
| Forecast Unit | Billion |
| Growth Rate | 9.71% |
| Study Period | 2015 to 2030 |
| Historical Data | 2015 to 2018 |
| Base Year | 2019 |
| Forecast Period | 2020 – 2030 |
| Segmentation | Product Type, Treatment Type, End User |
| Companies |
|
By Treatment Type: Conventional IVF
The Singaporean IVF treatment market, by treatment type, is segmented into Conventional IVF, ICSI (Intracytoplasmic Sperm Injection), Donor Egg IVF, Frozen Embryo Transfer (FET), and Others. Traditional IVF is the backbone of Singapore's Assisted Reproduction Industry, receiving continuous support from the public and Government, aided by regulatory and funding environment, and providing stability for the industry. Low Fertility Indicators at the National level display Singapore's Resident's Total Fertility Rate remaining below replacement level for 2023-2024, providing context for the continued importance of traditional IVF within the scope of broader Population and Family Building Policies. Public Assisted Reproduction Services (ARSCs) have had consistent volume over the last few years, suggesting that traditional IVF continues to be the main choice for couples struggling with infertility.
The Government's ability to provide financial support is crucial to maintaining stability within this market segment. In addition to the Ministry of Health's Assisted Conception Co-Funding Scheme, providing financial assistance to eligible Couples for both Fresh and Frozen Cycles, the MediSave Withdrawal Limits permit increased affordability for those choosing Traditional IVF. By making it easier for families to afford the up-front costs of treatment, these programs will help ensure that there are no financial barriers to patients accessing treatment. With many Clinics having consistent levels of Utilisation, particularly for Citizens and Permanent Residents using evidence-based standardised protocols for Traditional IVF, it is anticipated that usage of Traditional IVF sessions will continue to be steady.
From 2023-2025, Governmental Regulatory changes will impact this segment of the industry. Healthcare Services Act (HCSA) and Assisted Reproductive Services Regulations dictate the standards for Clinical Governance, Laboratory Processes, Regulatory Reporting Standards, and Patient Counselling. By having stricter requirements for these areas, this will raise the Quality Threshold of Traditional IVF Providers and establish more consistent delivery of services. Compliance with these regulations will not only increase the Operational Demands placed upon providers but will also build trust with patients and increase the safety and transparency of the overall Industry.
Singapore’s resident Total Fertility Rate fell to 0.97 in 2024, while total live births reached 33,703. This combination of a historically low fertility level and a relatively stable birth count highlights a widening gap between natural population replacement and actual reproductive outcomes. For the IVF treatment market, especially conventional IVF, this trend signals sustained demand. Couples are delaying childbirth because of career, financial, and lifestyle factors, leading to higher age-related infertility. As more individuals require medical support to conceive, conventional IVF remains the primary treatment pathway, keeping utilisation strong and reinforcing its central role within the country’s assisted reproduction landscape.
By End-User: Fertility Clinics
The Singaporean IVF treatment market, by end user, is segmented into Fertility Clinics, Hospitals, and Others. Singapore has established a network of assisted reproductive technology (ART) facilities, or clinics, to deliver ART services to individuals seeking to become parents through IVF treatment. The IVF market in Singapore is highly regulated to ensure patient safety, maintain high clinical standards, and provide accountability to patients. For an assisted reproduction clinic to be licensed and provide an ART programme, it must meet certain criteria established by national legislation regarding laboratory operations, documentation, and governance. Additionally, it ensures consistency regarding staff qualifications, procedures performed, and quality control measures implemented at each nationally licensed assisted reproduction clinic.
In addition to the national licensed assisted reproduction centres, which include and encompass the major hospital-based assisted reproduction programmes, numerous individual ART clinics, which are independently operated, have been established. Most of the ART clinics that are licensed by the Singapore Ministry of Health operate under the same guidelines established by the Ministry of Health, but they do not benefit from the same level of subsidy support that the national licensed assisted reproduction centres do. Thus, while assisted reproduction centres can utilise substantial government financial support for co-funding and withdrawal of patients’ MediSave, independent ART clinics provide additional alternatives to patients seeking ART treatment in Singapore by providing a greater variety of appointment flexibility, diagnostic package options, and custom-tailored care models.
All forms of ART can receive funding through the Co-Funding Scheme - for example, IVF and different combinations thereof, including IVF with or without ICSI. It will also provide funding to include gamete Intra-fallopian Transfer (GIFT). Patients receiving ART will have access to any routine services considered part of an individual's ART treatment plan. All treatments that are considered standard and that have evidence supporting their use in preparation before starting ART are eligible for the Co-Funding Scheme.